An innovative biotechnology start-up that develops promising small molecule-based therapies.
Saillant’s Recent History
Saillant Therapeutics B.V. is established in 2018 by Dr. Hamid el Azzouzi and Dr. Ad van Gorp. Recently joined by Dr. Joost van Bree as CEO, the team leverages its expertise in preclinical drug development to further validate and develop the promising therapeutic strategy of the ST-01 platform against acute ischemic stroke, heart failure (HF) and Alzheimer’s disease.
Saillant Therapeutics has a product pipeline covering novel compounds of which three therapeutic leads were selected. To date, seed financing has enabled the preclinical development and validation of the ST-01 analogs. It is the ambition of Saillant to advance its ST-01 platform also towards a variety of applications, resulting in at least one lead drug candidate reaching the clinic before the end of 2022.
Experts in the field
Meet Our Team
Dr. Hamid el Azzouzi
El Azzouzi set up a mouse cardiac surgery lab for transverse aortic constriction (TAC) induced pressure overload as a postdoctoral researcher at the Cardiology department at Maastricht University, publishing his work has in Cell Metabolism. At the department of cardiology in the UMCU and UM he focused on strategies to enhance cardiac regeneration after cardiac injury by creating a new surgical approach to unload the failing murine heart and used this model to study the regenerative potential of the heart. Together with Prof. P. Grundeman en Dr. F. Slochteren at the UMCU he setup pilot studies to design an effective way to unload large animal models as a regeneration model and as a possible therapy for ischemic cardiomyopathies. Next to this, he started a new research niche to study the role of RNA modifications in heart failure. This has generated exciting and new insights on how subtle single nucleotide modifications of RNA cause severe cardiac dysfunction.
Dr. Joost van Bree
Van Bree obtained an MSc and PharmD from Leiden University, after which he specialized and did his Ph.D. in Clinical Pharmacology, also from Leiden University. From 1995 onwards, he has worked in senior management positions and C-suite positions with responsibility for drug development, strategic development, regulatory affairs, business development, and private as well as public financing (IPO and Secondary Listing). He has gained extensive experience in strategic and operational hands-on management and leadership positions. He served in executive as well as non-executive director board positions with several public and private Life Science companies, amongst which were Sandoz/Novartis, Teva, Pharming, Noviogendix, Pepscan and Immunovo.
Dr. Ad van Gorp
Non Executive Director and Chairman
Van Gorp obtained an MSc in biology from the Utrecht University and did his PhD in Cardiac Physiology and Pharmacology at the University of Maastricht. He fullfilled 2 postdoc positions at the Univeristy of Leuven and University of Amsterdam. He worked at Janssen Pharmaceutica, Unilever, Danone and Kiadis in senior scientist positions. In 2005 he founded Lead Pharma and was CEO for 12 years. In 2015 Lead Pharma signed a large license deal with Sanofi on small molecule inhibitors of RORyt. The RORyt program is in clinical development. In 2018 he founded Cytura Therapeutics BV and Saillant Therapeutics BV. Van Gorp has extended experience in target discovery and development, strategic development and business development. He has gained extensive experience in strategic and operational hands-on management and leadership positions.
Ready to Make a Change?
By our full preclinical package, we will work together with you throughout the process until the commercialization of your drug candidate.